Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fundDr Arbat brings over 25 years’ pharma industry experience, including roles in women’s health at Bayer and OrganonOriva’s lead asset, ORV-362 - a non-hormonal, disease-modifying, first-in-class therapy for endometriosis - is already in Phase I clinical trials BARCELONA, Spain, June 11, 2026 (GLOBE NEWSWIRE) -- Oriva Therapeutics ('Oriva”), a women’s health company developing first-in-class and best-in-class approaches to treat chronic, prevalent conditions affecting women, today announces the appointment of seasoned biotech entrepreneur Dr Agnès Arbat as Chief Executive Officer.